LXR driven induction of HDL-cholesterol is independent of intestinal cholesterol absorption and ABCA1 protein expression

Kristina KannistoGösta Eggertsen


We investigated whether: (1) liver X receptor (LXR)-driven induction of high-density lipoprotein cholesterol (HDL-C) and other LXR-mediated effects on cholesterol metabolism depend on intestinal cholesterol absorption; and (2) combined treatment with the LXR agonist GW3965 and the cholesterol absorption inhibitor ezetimibe results in synergistic effects on cholesterol metabolism that could be beneficial for treatment of atherosclerosis. Mice were fed 0.2 % cholesterol and treated with GW3965+ezetimibe, GW3965 or ezetimibe. GW3965+ezetimibe treatment elevated serum HDL-C and Apolipoprotein (Apo) AI, effectively reduced the intestinal cholesterol absorption and increased the excretion of faecal neutral sterols. No changes in intestinal ATP-binding cassette (ABC) A1 or ABCG5 protein expression were observed, despite increased mRNA expression, while hepatic ABCA1 was slightly reduced. The combined treatment caused a pronounced down-regulation of intestinal Niemann-Pick C1-like 1 (NPC1L1) and reduced hepatic and intestinal cholesterol levels. GW3965 did not affect the intestinal cholesterol absorption, but increased serum HDL-C and ApoAI levels. GW3965 also increased Apoa1 mRNA levels in primary mouse hepatocytes and HEPA1-6 cells. ...Continue Reading


Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M RudlingB Angelin
Apr 1, 1989·Scandinavian Journal of Clinical and Laboratory Investigation·E LundI Bjorkhem
Jul 31, 1974·Clinica Chimica Acta; International Journal of Clinical Chemistry·I BjörkhemL Svensson
Nov 23, 2000·Genes & Development·J R SchultzB Shan
May 3, 2002·Journal of Medicinal Chemistry·Jon L CollinsTimothy M Willson
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sean B JosephPeter Tontonoz
Feb 21, 2004·Science·Scott W AltmannMichael P Graziano
Apr 21, 2005·The Journal of Clinical Investigation·Jenelle M TimminsJohn S Parks
Jan 18, 2006·Biochemical and Biophysical Research Communications·Caroline DuvalSophie Lestavel
Jan 27, 2006·European Journal of Clinical Investigation·P PariniM Rudling
Feb 28, 2006·The Journal of Biological Chemistry·Kei TakahashiKazumitsu Ueda
Mar 18, 2006·The Journal of Clinical Investigation·Liam R BrunhamMichael R Hayden
Jan 12, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Weiqing TangLiqing Yu
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Jan 30, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Tomoyuki YasudaDaniel J Rader
Nov 22, 2011·Current Opinion in Lipidology·Harry R DavisThomas Musliner
May 1, 2012·Trends in Pharmacological Sciences·Tomas JakobssonKnut R Steffensen
Aug 23, 2012·Vascular Health and Risk Management·Binh An P PhanPeter P Toth
Jul 3, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Xin BiJohn S Parks

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.